<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02492776</url>
  </required_header>
  <id_info>
    <org_study_id>7264-020</org_study_id>
    <secondary_id>AF219-020</secondary_id>
    <nct_id>NCT02492776</nct_id>
  </id_info>
  <brief_title>A Multiple-Dose Pharmacokinetics Study of Two Gefapixant (AF-219/MK-7264) Formulations</brief_title>
  <official_title>A Study in Healthy Subjects to Assess the Multiple-Dose Pharmacokinetics of Two AF-219 Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Afferent Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Afferent Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the multiple dose pharmacokinetics (PK) of two&#xD;
      gefapixant (AF-219) formulations; to assess the effect of omeprazole on the multiple dose PK&#xD;
      of two gefapixant formulations; and, to assess the safety and tolerability of gefapixant.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2015</start_date>
  <completion_date type="Actual">August 11, 2015</completion_date>
  <primary_completion_date type="Actual">August 4, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma concentration profiles of two different oral formulations of gefapixant</measure>
    <time_frame>12 hours</time_frame>
    <description>Plasma gefapixant concentration versus time profiles will be plotted for each subject; similar summary plots will be constructed for each treatment period. Plasma gefapixant PK parameters will be calculated using noncompartmental methods and summarized using descriptive statistics by each treatment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma concentration profile of gefapixant following administration of omeprazole</measure>
    <time_frame>5.5 hours</time_frame>
    <description>Analysis of variance (ANOVA) will be performed on log normal-transformed Cmax and AUC0-t values to determine the extent of a drug interaction, if any, of omeprazole on the plasma gefapixant PK parameters.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">14</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Gefapixant + Omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gefapixant oral tablets (25mg, 50 mg) administered twice daily for 13 days + Omeprazole oral capsules (20 mg) administered once daily for 8 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>20 mg oral capsules administered once daily for 8 days</description>
    <arm_group_label>Gefapixant + Omeprazole</arm_group_label>
    <other_name>Prilosec</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefapixant</intervention_name>
    <description>Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days</description>
    <arm_group_label>Gefapixant + Omeprazole</arm_group_label>
    <other_name>AF-219</other_name>
    <other_name>MK-7264</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gefapixant</intervention_name>
    <description>Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days</description>
    <arm_group_label>Gefapixant + Omeprazole</arm_group_label>
    <other_name>AF-219</other_name>
    <other_name>MK-7264</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must be informed of the nature of the study and have provided written informed&#xD;
             voluntary consent;&#xD;
&#xD;
          -  Able to speak, read, and understand English;&#xD;
&#xD;
          -  Healthy males or females, of any race, between 18 and 55 years of age, inclusive;&#xD;
&#xD;
          -  Body mass index (BMI) &gt;18.5 and &lt;32.0 kg/m2 and weigh 50 - 100 kg;&#xD;
&#xD;
          -  In good general health;&#xD;
&#xD;
          -  Non-smokers or intermittent (social) smokers for at least 5 years, and able to refrain&#xD;
             from smoking (or using nicotine) while in confinement;&#xD;
&#xD;
          -  If a female of child-bearing potential (i.e., have not undergone a hysterectomy or&#xD;
             bilateral oophorectomy) or not post-menopausal (defined as no menses for at least 12&#xD;
             months), agree to use 2 forms of acceptable birth control; or if a male, they and/or&#xD;
             their partner of child-bearing potential agree to use 2 forms of acceptable birth&#xD;
             control; when in line with the preferred life style of the subject, true and complete&#xD;
             abstinence (not periodic abstinence) is acceptable;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any disease or condition that might affect drug absorption, metabolism, or excretion&#xD;
             or clinically significant cardiovascular, hematological, renal, hepatic, pulmonary,&#xD;
             endocrine, gastrointestinal, immunological, dermatological, neurological, or&#xD;
             psychiatric disease;&#xD;
&#xD;
          -  Clinically significant illness or clinically significant surgery within 4 weeks before&#xD;
             the administration of study medication;&#xD;
&#xD;
          -  Any past sinus surgery, upper respiratory tract infection within 2 weeks before&#xD;
             dosing, or history of hay fever during the time of the year that dosing will be taking&#xD;
             place;&#xD;
&#xD;
          -  History of GERD, heartburn, or nausea more than once a month, or any similar symptoms&#xD;
             requiring the regular use of antacids, or any use of H2 histamine blockers or proton&#xD;
             pump inhibitors within 12 months of Screening;&#xD;
&#xD;
          -  Have a positive screening test for Helicobacter pylori;&#xD;
&#xD;
          -  QTcB &gt;450 msec in males or &gt;470 msec in females;&#xD;
&#xD;
          -  Known or suspected hypersensitivity or allergic reaction to any of the components of&#xD;
             gefapixant or omeprazole capsules;&#xD;
&#xD;
          -  If female, is pregnant or breast feeding, or has a positive pregnancy test pre dose;&#xD;
&#xD;
          -  Blood loss or blood donation of &gt;550 mL within 90 days or plasma donation &gt;500 mL&#xD;
             within 14 days before administration of the first dose of study drug;&#xD;
&#xD;
          -  Chronic use of any systemic medications (other than allowable oral and implanted&#xD;
             contraceptives and with the exception of vitamins taken at standard supplement doses);&#xD;
             use of a drug therapy (including herbal preparations, e.g., St. John's wort) known to&#xD;
             induce or inhibit hepatic drug metabolism within 30 days before the first dose of&#xD;
             study medication; or use of any medications [prescription or over the counter (OTC)],&#xD;
             including antacids, high dose multivitamins, nutritional supplements, and herbal&#xD;
             preparations, within 14 days before the first dose of study drug;&#xD;
&#xD;
          -  Past or current history or evidence of drug or alcohol abuse, regular use of more than&#xD;
             2 units of alcohol per day (1 unit of alcohol = 150 mL of wine, 360 mL of beer, or 45&#xD;
             mL of alcohol 40%), use of any recreational soft drugs (e.g., marijuana) within 3&#xD;
             months of screening, use of any hard drugs (such as cocaine, phencyclidine (PCP), and&#xD;
             crack) within 1 year of screening, and/or a positive screen for substances of abuse or&#xD;
             alcohol at screening or pre dose;&#xD;
&#xD;
          -  Ingestion of grapefruit or grapefruit juice within 48 hours before dose&#xD;
             administration;&#xD;
&#xD;
          -  Positive screen for hepatitis B surface antigen (HBsAg), hepatitis C antibody, or&#xD;
             human immunodeficiency virus (HIV) antibody;&#xD;
&#xD;
          -  Receipt of an investigational product or device, or participation in a drug research&#xD;
             study within a period of 30 days (or 5 half lives of the drug, whichever is longer)&#xD;
             before the first dose of study medication;&#xD;
&#xD;
          -  Receipt of an investigational immunomodulator or monoclonal antibody within 180 days&#xD;
             (or 5 half lives, whichever is longer) before the first dose of study medication.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dennis Swearingen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Celerion</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Tempe</city>
        <state>Arizona</state>
        <zip>85283</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <study_first_submitted>June 15, 2015</study_first_submitted>
  <study_first_submitted_qc>July 6, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2015</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

